359 related articles for article (PubMed ID: 24827753)
21. The Role of the IL-23/IL-17 Axis in Disease Initiation in Spondyloarthritis: Lessons Learned From Animal Models.
Mandour M; Chen S; van de Sande MGH
Front Immunol; 2021; 12():618581. PubMed ID: 34267743
[TBL] [Abstract][Full Text] [Related]
22. Canadian Rheumatology Association Consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis.
Maksymowych WP; Inman RD; Gladman D; Thomson G; Stone M; Karsh J; Russell AS;
J Rheumatol; 2003 Jun; 30(6):1356-63. PubMed ID: 12784417
[TBL] [Abstract][Full Text] [Related]
23. The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis.
Sieper J; Poddubnyy D; Miossec P
Nat Rev Rheumatol; 2019 Dec; 15(12):747-757. PubMed ID: 31551538
[TBL] [Abstract][Full Text] [Related]
24. Whodunit? The Contribution of Interleukin (IL)-17/IL-22-Producing γδ T Cells, αβ T Cells, and Innate Lymphoid Cells to the Pathogenesis of Spondyloarthritis.
Reinhardt A; Prinz I
Front Immunol; 2018; 9():885. PubMed ID: 29922283
[TBL] [Abstract][Full Text] [Related]
25. Spondyloarthritis: from unifying concepts to improved treatment.
Paramarta JE; Baeten D
Rheumatology (Oxford); 2014 Sep; 53(9):1547-59. PubMed ID: 24369419
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-23 mediates the intestinal response to microbial β-1,3-glucan and the development of spondyloarthritis pathology in SKG mice.
Benham H; Rehaume LM; Hasnain SZ; Velasco J; Baillet AC; Ruutu M; Kikly K; Wang R; Tseng HW; Thomas GP; Brown MA; Strutton G; McGuckin MA; Thomas R
Arthritis Rheumatol; 2014 Jul; 66(7):1755-67. PubMed ID: 24664521
[TBL] [Abstract][Full Text] [Related]
27. The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond.
Dubash S; Bridgewood C; McGonagle D; Marzo-Ortega H
Expert Rev Clin Immunol; 2019 Feb; 15(2):123-134. PubMed ID: 30576610
[TBL] [Abstract][Full Text] [Related]
28. Use of brodalumab for the treatment of psoriasis and psoriatic arthritis.
Kivelevitch DN; Menter A
Immunotherapy; 2015; 7(4):323-33. PubMed ID: 25917624
[TBL] [Abstract][Full Text] [Related]
29. [Ocular involvement in spondylarthritis--new mechanisms, new therapies].
Itulescu TC; Alexandrescu C; Voinea LM
Oftalmologia; 2014; 58(1):27-35. PubMed ID: 25145120
[TBL] [Abstract][Full Text] [Related]
30. New developments in ankylosing spondylitis-status in 2021.
Klavdianou K; Tsiami S; Baraliakos X
Rheumatology (Oxford); 2021 Dec; 60(Suppl 6):vi29-vi37. PubMed ID: 34951921
[TBL] [Abstract][Full Text] [Related]
31. IL-23/IL-17 axis in spondyloarthritis-bench to bedside.
Raychaudhuri SP; Raychaudhuri SK
Clin Rheumatol; 2016 Jun; 35(6):1437-41. PubMed ID: 27075462
[TBL] [Abstract][Full Text] [Related]
32. IL-23 responsive innate-like T cells in spondyloarthritis: the less frequent they are, the more vital they appear.
Venken K; Elewaut D
Curr Rheumatol Rep; 2015 May; 17(5):30. PubMed ID: 25874346
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-17A Inhibition Diminishes Inflammation and New Bone Formation in Experimental Spondyloarthritis.
van Tok MN; van Duivenvoorde LM; Kramer I; Ingold P; Pfister S; Roth L; Blijdorp IC; van de Sande MGH; Taurog JD; Kolbinger F; Baeten DL
Arthritis Rheumatol; 2019 Apr; 71(4):612-625. PubMed ID: 30390386
[TBL] [Abstract][Full Text] [Related]
34. Interleukin 27 is a novel cytokine with anti-inflammatory effects against spondyloarthritis through the suppression of Th17 responses.
Jouhault Q; Cherqaoui B; Jobart-Malfait A; Glatigny S; Lauraine M; Hulot A; Morelle G; Hagege B; Ermoza K; El Marjou A; Izac B; Saintpierre B; Letourneur F; Rémy S; Anegon I; Boissier MC; Chiocchia G; Breban M; Araujo LM
Front Immunol; 2022; 13():1072420. PubMed ID: 36818477
[TBL] [Abstract][Full Text] [Related]
35. Spondyloarthritis in 2012: Advances in pathogenesis through animal models and imaging.
Maksymowych WP
Nat Rev Rheumatol; 2013 Feb; 9(2):72-4. PubMed ID: 23296391
[TBL] [Abstract][Full Text] [Related]
36. Paradoxical Augmentation of Experimental Spondyloarthritis by RORC Inhibition in HLA-B27 Transgenic Rats.
van Tok MN; Mandour M; Wahle J; Labadia ME; van de Sande MGH; Nabozny G; Baeten DL; van Duivenvoorde LM
Front Immunol; 2021; 12():699987. PubMed ID: 34552583
[TBL] [Abstract][Full Text] [Related]
37. Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis.
Melis L; Vandooren B; Kruithof E; Jacques P; De Vos M; Mielants H; Verbruggen G; De Keyser F; Elewaut D
Ann Rheum Dis; 2010 Mar; 69(3):618-23. PubMed ID: 19196728
[TBL] [Abstract][Full Text] [Related]
38. Psoriatic arthritis and spondyloarthritis assessment and management update.
Mease P
Curr Opin Rheumatol; 2013 May; 25(3):287-96. PubMed ID: 23492739
[TBL] [Abstract][Full Text] [Related]
39. Th17 cells and IL-17 a--focus on immunopathogenesis and immunotherapeutics.
van den Berg WB; McInnes IB
Semin Arthritis Rheum; 2013 Oct; 43(2):158-70. PubMed ID: 24157091
[TBL] [Abstract][Full Text] [Related]
40. IL-17 inhibition in axial spondyloarthritis: current and future perspectives.
Torgutalp M; Poddubnyy D
Expert Opin Biol Ther; 2019 Jul; 19(7):631-641. PubMed ID: 30957574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
